Enzyme inhibition kinetics experiment

Enzyme Inhibition Kinetics Experiment – Mechanistic Characterisation and Potency Determination for Drug Discovery, Agrochemical Development and Industrial Biocatalysis

As an ISO/IEC 17025 accredited contract research laboratory, we offer comprehensive enzyme inhibition kinetics experimentation services to Bulgarian and international clients in pharmaceutical, agrochemical, biotechnology, and food ingredient sectors. Enzyme inhibitors are key therapeutic agents (e.g., ACE inhibitors, kinase inhibitors, proteasome inhibitors), pesticide leads, and modulators of industrial enzyme performance. Understanding the mechanism of inhibition – whether competitive, uncompetitive, non‑competitive, or mixed – and accurately determining the inhibition constant (Ki) and half‑maximal inhibitory concentration (IC₅₀) are essential for lead optimisation, mode‑of‑action studies, and regulatory submissions. Our kinetic platform combines steady‑state and pre‑steady‑state methods, using both conventional spectrophotometry and high‑throughput microplate readers, to deliver reliable kinetic parameters. All studies are designed in accordance with ICH Q2(R1) (Validation of Analytical Procedures), OECD guidelines for enzyme‑based assays, and BDS (Bulgarian Institute for Standardisation) recommendations. Our reports are recognised by the Bulgarian Drug Agency (BDA), the Bulgarian Food Safety Agency (BFSA), and leading research and industrial partners for drug development, agrochemical registration, and biocatalyst optimisation.

Enzyme Systems and Inhibitor Types We Investigate

Our kinetic laboratory handles a wide range of enzyme classes and inhibitor candidates. Typical test systems include:

Oxidoreductases – cytochrome P450, horseradish peroxidase, lactate dehydrogenase, glucose oxidase
Transferases – kinases (e.g., protein kinase A, EGFR kinase), aminotransferases, glycosyltransferases
Hydrolases – proteases (trypsin, chymotrypsin, caspases), phosphatases, lipases, acetylcholinesterase
Lyases – aldolases, carbonic anhydrase
Isomerases – triosephosphate isomerase, phosphoglucose isomerase
Ligases – DNA ligase, ubiquitin ligase
Inhibitor types – reversible inhibitors (competitive, uncompetitive, non‑competitive, mixed), irreversible inhibitors, and time‑dependent (slow‑binding) inhibitors
Test compounds – small molecules, natural extracts, peptide‑based inhibitors, antibodies, and fragment libraries
Substrate and cofactor ranges – chromogenic, fluorogenic, luminescent, or native substrates; NAD(P)H, ATP, coenzyme A, etc.

Experimental Design – Steady‑State and Pre‑Steady‑State Kinetics

Choice of assay format – continuous or endpoint – We select the most suitable assay format based on the enzyme and substrate: (a) continuous monitoring (UV‑Vis absorbance, fluorescence, or luminescence) for real‑time progress curves, or (b) endpoint assays where the reaction is stopped after a fixed time (e.g., using acid or a stop buffer) and product quantitated. For high‑throughput screening, we prefer endpoint or initial‑rate assays in 96‑ or 384‑well microplates.
Determination of optimal assay conditions – Prior to inhibition studies, we establish the optimal pH, temperature, buffer composition, ionic strength, and cofactor concentration for each enzyme‑substrate pair. The enzyme concentration is adjusted so that the initial velocity (v₀) is linear with time and proportional to enzyme concentration (typically ≤ 10 % substrate conversion).
Substrate concentration range – Michaelis‑Menten curve – We perform a full substrate saturation curve (typically 6‑10 substrate concentrations spanning 0.1‑10× Km) in the absence of inhibitor to determine the apparent Km and Vmax under the assay conditions. The Km value is used to design the inhibition experiments.
Inhibitor concentration range – covering 0 to 10× IC₅₀ – For each inhibitor, we test at least 8‑10 concentrations (plus a no‑inhibitor control) in duplicate or triplicate. The concentration range is selected to encompass the expected IC₅₀ (determined from preliminary screening) and to cover a broad range of fractional inhibition (0‑90 %).
Pre‑incubation and time‑dependence – For time‑dependent (slow‑binding) inhibitors, we include a pre‑incubation step (e.g., 0, 15, 30, 60 minutes) before initiating the reaction by substrate addition. The progress curves are monitored continuously to detect slow onset of inhibition and to determine the rate constants for inhibition and reactivation.
Controls – each plate includes: (a) a positive control (enzyme + substrate, no inhibitor) for 100 % activity, (b) a negative control (no enzyme, no substrate) for background correction, (c) a standard inhibitor (e.g., with known Ki) to validate the assay performance.

Data Collection – Initial Velocity and Progress Curve Analysis

Initial rate determination – For continuous assays, we measure the linear increase in product (or decrease in substrate) over the first 5‑10 % of the reaction. The slope of the linear region (ΔAbs/Δt or ΔFluorescence/Δt) is calculated for each well and converted to reaction velocity (μmol/min/mg or μmol/min/mL) using a calibration curve of product standard.
Endpoint assays – For endpoint assays (e.g., colorimetric or coupled enzyme assays), the reaction is stopped after a fixed time (t) and the product concentration is measured. The velocity is calculated as (product concentration / t).
Progress curves for time‑dependent inhibition – For slow‑binding inhibitors, we fit the entire progress curve (product vs. time) to a single exponential or a two‑phase exponential model (Equation: P = v₀·t + (v₀ – vₛ)·(1 – e⁻ᵏᵒᵇˢ·ᵗ)/kᵒᵇˢ) to obtain the initial velocity (v₀), the steady‑state velocity (vₛ), and the observed rate constant (kᵒᵇˢ).

Kinetic Parameter Determination – Km, Vmax, and Ki

Determination of Km and Vmax – Michaelis‑Menten (non‑linear) and Lineweaver‑Burk (double‑reciprocal) methods – From the substrate saturation curves (velocity vs. [S]), we fit the data to the Michaelis‑Menten equation (v = Vmax·[S]/(Km + [S])) using non‑linear regression (e.g., GraphPad Prism, SigmaPlot). The apparent Km and Vmax for each inhibitor concentration are obtained. We also plot the data as 1/v vs. 1/[S] (Lineweaver‑Burk) for visual inspection of the inhibition pattern (intersecting or parallel lines).
IC₅₀ determination – concentration‑response curves – From the inhibitor dose‑response data (velocity vs. [I]) at a fixed substrate concentration (typically ≤ Km), we fit the data to a four‑parameter logistic equation: Relative Activity (%) = Bottom + (Top – Bottom) / (1 + 10^((LogIC₅₀ – Log[I])·HillSlope)). The IC₅₀ (the concentration of inhibitor that reduces enzyme activity by 50 %) and the Hill coefficient are reported. For competitive inhibitors, IC₅₀ is related to Ki by the Cheng‑Prusoff equation: IC₅₀ = Ki × (1 + [S]/Km) when the inhibitor is competitive and the substrate concentration is below Km.
Ki determination – for reversible inhibitors – We determine the inhibition constant (Ki) from the dependence of the apparent Km and/or Vmax on inhibitor concentration. For competitive inhibition: Km_app = Km × (1 + [I]/Ki), while Vmax remains unchanged. We plot Km_app vs. [I] (or 1/Km_app vs. [I]) and determine Ki from the slope/intercept. For non‑competitive inhibition: Vmax_app = Vmax / (1 + [I]/Ki), and Km is unchanged. For uncompetitive inhibition: both Km_app and Vmax_app are affected, and the ratio Vmax_app/Km_app is constant.
Discrimination of inhibition type – by global fitting of kinetic data – We perform global fitting of the entire dataset (velocities at all substrate and inhibitor concentrations) to the general equation for reversible inhibition (competitive, non‑competitive, uncompetitive, or mixed) using non‑linear regression. The best‑fit model is selected based on the Akaike Information Criterion (AIC) or F‑test.
Time‑dependent inhibition – mechanism and rate constants – For slow‑binding, irreversible, or mechanism‑based inhibitors, we determine the pseudo‑first‑order rate constant for inhibition (kₒbₛ) at different inhibitor concentrations, and from the linear relationship between kₒbₛ and [I], we obtain the rate of inhibition (k₂) and the initial complex dissociation constant (Ki).

Data Analysis and Software Tools

Non‑linear regression software – we use GraphPad Prism, SigmaPlot, and Origin for curve fitting (Michaelis‑Menten, dose‑response, and inhibition models). All models include weighting (e.g., 1/Y²) to account for heteroscedasticity.
Statistical evaluation – each experiment is performed in at least three independent replicates; the results are expressed as mean ± standard deviation (SD) or standard error of the mean (SEM). 95 % confidence intervals are provided for fitted parameters (Km, Vmax, IC₅₀, Ki).
Goodness‑of‑fit assessment – we report R², residual plots, and the standard error of the estimate to assess the adequacy of the model.
Comparison of inhibition types – using the Akaike Information Criterion (AIC) – when multiple inhibition models are possible (e.g., competitive vs. non‑competitive), we perform model comparison using the AIC to select the most parsimonious model.
Confidence intervals for Ki – by the Fieller’s theorem or bootstrapping – for reliable reporting, we provide 95 % confidence intervals for Ki (or IC₅₀) using bootstrapping (1 000 resamples).

Assay Validation and Quality Control

To ensure the accuracy and reliability of kinetic parameters, we implement rigorous quality control measures.

Enzyme stability – activity retention under assay conditions – we verify that the enzyme retains ≥ 90 % of its activity over the duration of the assay (including pre‑incubation periods) by performing control incubations without inhibitor.
Substrate depletion check – ensuring initial rate conditions – we ensure that ≤ 10 % of the substrate is consumed during the measurement period, to avoid substrate depletion effects and maintain linearity.
Reagent quality – use of certified reference standards and certified purity substrates – we use high‑purity substrates (≥ 98 %) and reference inhibitors (≥ 98 %) from reputable suppliers (e.g., Sigma‑Aldrich, Enzo Life Sciences).
Temperature control – maintaining constant temperature (±0.1 °C) – the assay is performed in a temperature‑controlled microplate reader or spectrophotometer with a Peltier temperature control module.
Plate uniformity and edge effect assessment – for microplate assays – we check for any well‑to‑well variation by performing a blank (no enzyme) and a 100 % activity control across the plate; the coefficient of variation (CV) is ≤ 5 %.
Calibration of detection instruments – spectrophotometers and fluorometers – we calibrate the absorbance and fluorescence detectors using standard reference materials (e.g., NIST‑traceable filters or fluorescein standards).
Blind testing and proficiency testing – we participate in inter‑laboratory comparison studies for enzyme kinetics (e.g., through the National Measurement Institute or external proficiency schemes) to verify the accuracy of our methods.

Case‑Specific Applications – Drug Discovery, Pesticide Development and Biocatalysis

Lead optimisation – identifying the most potent and selective inhibitors – we test a series of structural analogues against the target enzyme to rank their potency (IC₅₀ or Ki) and selectivity (ratio of Ki for target vs. off‑target enzymes). This helps to select the best candidates for further development.
Mechanism of action studies – elucidating the binding mode – by comparing the inhibition type (competitive, non‑competitive, etc.) and the Ki value, we provide insights into the inhibitor’s binding site and its interaction with the enzyme. This is essential for structure‑activity relationship (SAR) studies and for intellectual property claims.
Interaction with physiological substrates – for in vivo relevance – for potential therapeutic inhibitors, we measure the Ki and IC₅₀ in the presence of physiological concentrations of substrates, cofactors, and protein binding (e.g., serum albumin) to assess the potential for efficacy in vivo.
High‑throughput screening (HTS) of inhibitor libraries – for drug discovery – we offer HTS campaigns using 384‑well microplate formats, with automated liquid handling and rapid readout, to screen thousands of compounds for their ability to inhibit the target enzyme. We then perform kinetic characterisation on the hits (IC₅₀, Ki, inhibition type).
Agrochemical inhibitors – targeting plant enzymes (e.g., herbicides, fungicides) – we test inhibitors against plant‑specific enzymes (e.g., acetolactate synthase, EPSP synthase, cytochrome P450) to evaluate their potency and selectivity against mammalian homologues, supporting Bulgarian and European agrochemical registration.
Industrial biocatalysis – enzyme stability and inhibitor tolerance – for enzymes used in industrial processes (e.g., proteases in detergents, lipases in biodiesel production), we determine the inhibition constants for process impurities, product inhibitors, and contaminants to predict process performance and to establish process control strategies.

Reporting – Comprehensive Documentation for Regulatory and Publication Purposes

Our final enzyme inhibition kinetics report provides a complete record of the experimental design, data, and interpretation. The report includes:

Sample and assay information – enzyme source, substrate, inhibitor details, assay conditions (pH, temperature, buffer), and instrument settings
Raw data – substrate saturation curves, dose‑response curves, progress curves (for time‑dependent inhibitors), and replicate data
Fitted parameters – Km, Vmax, IC₅₀, Ki (with 95 % confidence intervals), Hill coefficient, and the best‑fit inhibition model (competitive, uncompetitive, etc.)
Statistical summary – mean ± SD, 95 % CI, R² values, and residual plots
Graphical presentations – Michaelis‑Menten and Lineweaver‑Burk plots, dose‑response curves, and, where appropriate, global fits of the kinetic data
Conclusions and interpretation – a clear statement of the inhibitor’s potency, mechanism of inhibition, and the significance of the results for the client’s intended application (drug development, agrochemical registration, etc.)

Report Acceptance & Compliance with Bulgarian and European Regulatory Standards

All enzyme inhibition kinetics experiments are performed under our ISO/IEC 17025 accreditation and in compliance with ICH Q2(R1) validation guidelines and Good Laboratory Practice (GLP) principles, where applicable. Our reports are accepted by the Bulgarian Drug Agency (BDA), the Bulgarian Food Safety Agency (BFSA), and international pharmaceutical and agrochemical companies for lead optimisation, mechanism of action studies, and regulatory submissions. Bilingual (Bulgarian/English) versions are available to facilitate submissions to national and European authorities.